Clinical trials: Glucagon
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
- Trial name
- SURPASS-CVOT (NCT04255433)
- Testing
- Tirzepatide, Dulaglutide
- Where
- 635 sites in United States, Argentina and 29 more
- Volunteers
- 13,299 people
- Sponsor
- Eli Lilly and Company
To Assess the Impact of Bile Acids on Human Glukagon-like-peptide-1 Secretion
The Impact of Gall Bladder Emptying and Bile Acids on the Human GLP-1-secretion
The last couple of years it has been shown that bile acids not only acts as simple emulsifiers of fat, but constitutes a complex metabolic integrator which not only have an influence on fat digestion and lipid metabolism, but…
- Trial name
- NCT01656057
- Testing
- Acetaminophen, Metformin, Colesevelam
- Where
- Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Filip Krag Knop
Opioid Use Disorder, Opioid Abuse and Addiction
GLP-1R Agonist Treatment for Opioid Use Disorder
The goal of this clinical trial is to learn if semaglutide can reduce illicit opioid use in adults in outpatient treatment for opioid use disorder, and who are receiving either buprenorphine or methadone maintenance treatment.
- Conditions
- Opioid Use Disorder, Opioid Abuse and Addiction, Narcotic-Related Disorders, Substance-Related Disorders
- Trial name
- NCT06548490
- Testing
- Semaglutide Pen Injector
- Where
- 4 sites in United States
- Volunteers
- 200 people
- Sponsor
- Milton S. Hershey Medical Center
Chronic Kidney Diseases
The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect
CAPTIVATE is an international, multi-centre, Phase III, adaptive, platform, randomised controlled trial in people with chronic kidney disease (CKD).
- Trial name
- CAPTIVATE (NCT06058585)
- Testing
- Finerenone, Semaglutide
- Where
- 51 sites in Australia, India and 3 more
- Volunteers
- 2,000 people
- Sponsor
- The George Institute
Diabetes Mellitus, Type 1, Hypoglycemia
The Role of Glucose-Dependent Insulinotropic Polypeptide in the Pathological Glucose Homeostasis Of Type 1 Diabetes
In the present project the investigators will evaluate whether glucagonotropic properties of the gut-derived incretin hormone glucose-dependent insulinotropic polypeptide (GIP) may be utilized as a safeguard against hypoglycemia…
- Trial name
- NCT03734718
- Testing
- GIP
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Steno Diabetes Center Copenhagen
Coronary Angiography, Glucagon-Like Peptide 1
Plasma GLP1 and Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention
The purpose of this study is to evaluate the predicting role of plasma GLP1 level on major adverse cardiovascular events (MACE) in patients with acute myocardial infarction who undergo percutaneous coronary intervention.
- Trial name
- NCT02846168
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chinese PLA General Hospital
Hypoglycemia, Diabetes Mellitus, Type 1
A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus
The trial's objective is to evaluate the immunogenicity of repeated single doses of dasiglucagon* and GlucaGen following subcutaneous (SC) administration in patients with type 1 diabetes mellitus (T1DM) and further to evaluate…
- Trial name
- NCT03216226
- Testing
- dasiglucagon, GlucaGen
- Where
- 7 sites in United States, Austria and 2 more
- Volunteers
- 112 people
- Sponsor
- Zealand Pharma
Atherosclerosis, Diabetes
Effects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes Subjects
The aim of the study is to use Exenatide long-acting release (LAR) [Bydureon] to minimize vascular remodeling and neointima formation after Percutaneous Coronary Intervention (PCI) and to accelerate stent endothelialisation.
- Conditions
- Atherosclerosis, Diabetes, Restenosis
- Trial name
- Rebuild (NCT02621489)
- Testing
- Bydureon, Humulin kwickpen, Metformin
- Where
- Sweden
- Volunteers
- 38 people
- Sponsor
- Karolinska Institutet
Hypoglycemia
Effect of Fasting on Insulin-induced Hypoglycemia Counterregulation in Healthy Humans
Iatrogenic hypoglycemia is still considered to be the number one barrier to effective glycemic control in patients with type 1 diabetes (T1D).
- Trial name
- NCT04392843
- Testing
- Fasting, Feeding
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Cincinnati
Type 2 Diabetes, Obesity
Relationship Between Changes in Gut Hormones After Gastric Bypass and Gastric Banding and Improvements in Diabetes
The purpose of this study is to see how hormones that control blood sugar change in response to two different weight loss surgeries (gastric bypass and gastric banding).
- Conditions
- Type 2 Diabetes, Obesity, Bariatric Surgery
- Trial name
- NCT01153438
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Pennsylvania
Gastric Ultrasound, Glucagon-like Peptide 1
Gastric Ultrasound Assessment for Patients Taking GLP1 Agonists
The aim of this study is to perform bedside gastric point of care ultrasound (POCUS) exams to assess the gastric volume and content (clear liquids vs solid food) perioperatively in patients who take glucagon-like peptide 1…
- Conditions
- Gastric Ultrasound, Glucagon-like Peptide 1, Point of Care Ultrasound
- Trial name
- NCT06003985
- Testing
- Gastric Ultrasound Exam
- Where
- 8 sites in United States, Canada
- Volunteers
- 354 people
- Sponsor
- Hospital for Special Surgery, New York
Type 2 Diabetes, Chronic Kidney Diseases
Impact of GLP-1 RAs Compared to Basal Insulin Start in Patients Living With Type 2 Diabetes and Chronic Kidney Disease
The overall objective of this study is to compare the effectiveness of adding a glucagon-like peptide-1 receptor agonist compared with adding basal insulin for patients with type 2 diabetes and chronic kidney disease, already…
- Trial name
- NCT06236672
- Testing
- GLP-1 receptor agonist, basal insulin
- Where
- Canada
- Volunteers
- 348 people
- Sponsor
- LMC Diabetes & Endocrinology Ltd.
Healthy
A Study Comparing User Experience of Different Delivery Devices for Glucagon
The purpose of the study is to learn more about different devices for delivering glucagon during simulations of severe hypoglycemic (low blood sugar) emergencies.
- Trial name
- NCT03765502
- Testing
- Nasal Glucagon Device (NG), GEK, IM Glucagon
- Where
- United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Pre-diabetes
The Role of Cholinergic Signaling for Mediating the Effects of GIP and/or Xenin-25 on Insulin Secretion
Glucose-dependent insulinotropic polypeptide (GIP) is a hormone produced in the intestine. It is released immediately after meal ingestion and increases insulin release. This, in turn, helps reduce blood glucose levels.
- Trial name
- NCT01951729
- Testing
- Control, Xenin-25 without atropine, GIP without atropine
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Hypoglycemia
PK/PD Study With G-Pump (Glucagon Infusion) in T1DM Patients
The purpose of the study is to assess the safety, speed of absorption, and onset of action of G-Pump™ (glucagon infusion) at three subcutaneous doses as compared to Novo GlucaGen®, all delivered via an OmniPod® infusion pump to…
- Trial name
- NCT02081001
- Testing
- Novo Nordisk GlucaGen®, G-Pump™ (glucagon infusion)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Xeris Pharmaceuticals
Opiate Substitution Treatment, Opioid-Related Disorders
Use of a GLP-1R Agonist to Treat Opioid Use Disorder
This research is being done to find out if liraglutide (brand name is Saxenda®) can safely and effectively reduce craving for opioids in patients with opioid use disorder, a primary factor contributing to early relapse.
- Trial name
- NCT04199728
- Testing
- Liraglutide Pen Injector
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Milton S. Hershey Medical Center
Myocardial Infarction
GLP-1 on Non-ST-Segment Elevation Myocardial Infarction
The investigators planned to evaluate the effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction (NSTEMI).
- Trial name
- NCT02577848
- Testing
- GLP-1
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Chinese PLA General Hospital
Type 2 Diabetes
A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
This is a multicenter, randomized, double-blind, active-controlled, parallel-group study, which aims to provide data on the efficacy and safety of HDM1002 tablets compared with dapagliflozin in adults with type 2 diabetes…
- Trial name
- NCT07082114
- Testing
- HDM1002 100 mg, HDM1002 200 mg, HDM1002 400 mg
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Hypoglycemia Unawareness, Diabetes Mellitus, Type 1
Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses
This is a prospective, randomized, controlled, double-blind, parallel 4-group trial with the primary analysis after 4 weeks of treatment with continuous subcutaneous glucagon infusion (CSGI) or placebo.
- Trial name
- NCT03490942
- Testing
- Glucagon
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Xeris Pharmaceuticals
Blood Flow
The Role of GIP and GLP-2 in Postprandial Splanchnic Blood Flow Distribution and Metabolism
This project will describe the mechanisms of action and the relative contributions of GIP and GLP-2 to changes in gastrointestinal blood flow induced by oral glucose, exogenous GIP and GLP-2 infusions, and endogenous GIP and…
- Trial name
- GA-17 (NCT05391581)
- Testing
- GIPR antagonist / study tool, GLP-2R antagonist / study tool
- Where
- Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen